research Impact of taxol on dermal papilla cells — A proteomics and bioinformatics analysis
Taxol damages hair growth cells, causing hair loss.
Search
for
Sort by
Research
390-420 / 1000+ results research TRAIL sensitization of PC3 prostate cancer cells by doxorubicin can be blocked by the anti-oxidant N-acetyl-cysteine or by the iron chelator deferoxamine
Antioxidants can block the cancer-fighting effects of doxorubicin.
research Combinatorial Therapy of Letrozole- and Quercetin-Loaded Spanlastics for Enhanced Cytotoxicity against MCF-7 Breast Cancer Cells
Combining letrozole and quercetin in spanlastics may improve breast cancer treatment.
research Frozen Glove Therapy for Docetaxel-Induced Hand Problems May Not Fit All
Wearing a frozen glove during chemotherapy can reduce nail and skin problems but may not be comfortable for everyone.
research Mesotherapy with dutasteride in the treatment of androgenetic alopecia
research Original synthetic monophenolic antioxidant with combined effect inhibits tumor growth in vivo
TS-13 effectively stops tumor growth and reduces chemotherapy side effects.
research Combination of Western Medicine and Traditional Chinese Medicine for Treatment of Malignant Bone and Soft Tissue Tumors
Combining Western chemotherapy with Traditional Chinese Medicine can reduce side effects and improve immune response in treating bone and soft tissue tumors.
research Noyes-Whitney Dissolution Model-Based pH-Sensitive Slow Release of Paclitaxel (Taxol) from Human Hair-Derived Keratin Microparticle Carriers
Human hair-derived particles can effectively carry and release the cancer drug Paclitaxel in a pH-sensitive manner, potentially targeting cancer cells while sparing healthy ones.
research Hair regrowth in endocrine therapy alopecia with dutasteride treatment in woman with estrogen positive breast cancer
research Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatment
Scalp cooling significantly reduces hair loss in chemotherapy patients.
research A novel derivative of doxorubicin, AD198, inhibits canine transitional cell carcinoma and osteosarcoma cells in vitro
AD198 is more effective than doxorubicin in stopping certain dog cancer cells.
research Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
Cancer treatments often cause skin, nail, and hair problems.
research Fabrication and in vitro evaluation of silk fibroin-folic acid decorated paclitaxel and hydroxyurea nanostructured lipid carriers for targeting ovarian cancer cells: A double sword approach
The new drug carriers show promise for better targeting and treating ovarian cancer.
research Annurca Apple Polyphenols Protect Murine Hair Follicles from Taxane Induced Dystrophy and Hijacks Polyunsaturated Fatty Acid Metabolism toward β-Oxidation
Annurca apple extract may protect mouse hair from damage by chemotherapy and could help treat hair loss without promoting cancer growth.
research ORAL TARGETED THERAPY-INDUCED CUTANEOUS TOXICITY: LIFE EXPERIENCE OF PATIENTS WITH ADVANCED LUNG CANCER IN TAIWAN
More research is needed to understand chemotherapy-induced hair loss and its phases.
research Effect of adenosine triphosphate on ribociclib-induced skin toxicity in rats
research Upadacitinib: A New Weapon for the Treatment of Twenty-Nail Dystrophy
Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.
research Supplementary Material for: Patient Preferences: Results of a German Adaptive Choice-Based Conjoint Analysis (Market Research Study Sponsored by Eli Lilly and Company) in Patients on Palliative Treatment for Advanced Breast Cancer
Quality of life, overall survival, and progression-free survival should be equally prioritized in advanced breast cancer treatment decisions.
research A Prospective Observational Study for Assessment of Chemotherapy-Induced Adverse Drug Reactions in Cancer Patients
Females had more chemotherapy side effects than males, with many being preventable.
research New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics
New drugs and therapies targeting specific pathways show promise in treating advanced prostate cancer.
research Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome
Neoadjuvant chemotherapy followed by surgery leads to fewer severe complications and better quality of life than immediate surgery in advanced ovarian cancer patients with high tumor load.
research Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
Upadacitinib improved multiple immune-related conditions in one patient.
research Supplementary Material for: Patient Preferences: Results of a German Adaptive Choice-Based Conjoint Analysis (Market Research Study Sponsored by Eli Lilly and Company) in Patients on Palliative Treatment for Advanced Breast Cancer
Patients with advanced breast cancer prioritize quality of life, overall survival, and progression-free survival in treatment decisions.
research Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment
New targeted cancer drugs can cause skin side effects, and managing them requires patient education and timely care.
research Single‐center study to determine the safety and efficacy of CT‐707 in Chinese patients with advanced anaplastic lymphoma kinase‐rearranged non‐small‐cell lung cancer
CT-707 is effective and safe for treating certain Chinese lung cancer patients.
research 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
research Etoposide sensitizes CT26 colorectal adenocarcinoma to radiation therapy in BALB/c mice
Etoposide makes radiation therapy more effective against tumors without major side effects.
research 532P Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011)
Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
research Chemotherapieinduzierte Alopezie
Chemotherapy causes temporary hair loss and discomfort, while tamoxifen has minimal hair effects.
research Journal for ReAttach Therapy and Developmental Diversities
Ayurveda-based care improved quality of life for breast cancer patients without serious side effects.